In what CEO Mark Murray told BioWorld Today may signal "the first of a number of deals," hepatitis B virus (HBV)-focused Arbutus Biopharma Corp. is bringing aboard $7.5 million up front and as much as $75 million in development, regulatory and commercial milestone payments from Alexion Pharmaceuticals Inc. for the lipid nanoparticle (LNP) technology.